Figure 3.

Comparative study of antitumor activities against human multiple myeloma after intravenous delivery of the viruses. (a) Survival curves of mice with systemic multiple myeloma. A disseminated model of multiple myeloma was established in mice as described in materials and methods. Mice were treated with three doses of 10⁷ TCID₅₀ of the indicated viruses. *Statistically significant difference between VSV-FH and saline (Logrank test, P < 0.0001) or VSV-M51-NIS (P = 0.0124). Arrows indicate virus injection days (post-KAS 6/1 implantation). (b) Mice bearing subcutaneous plasmacytomas of human multiple myeloma were treated with one dose of the following viruses: Saline (n = 8), MV (n = 6), VSV-FH (n = 7), or VSV-M51-NIS (n = 8). Plasmacytoma volumes were measured three times per week and plotted on a logarithmic scale. Error bars represent SEM. (c) Survival curves of mice with subcutaneous multiple myeloma. *Significant difference between VSV-FH and saline (P = 0.001), MV-NIS (P = 0.0354), or VSV-M51-NIS (P = 0.0011). MV, measles virus; VSV, vesicular stomatitis virus.